<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085202</url>
  </required_header>
  <id_info>
    <org_study_id>SJMB03</org_study_id>
    <secondary_id>NCI-2011-01185</secondary_id>
    <nct_id>NCT00085202</nct_id>
  </id_info>
  <brief_title>Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor</brief_title>
  <official_title>Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drugs used in chemotherapy, such as vincristine, cisplatin, and cyclophosphamide, work in
      different ways to stop tumor cells from dividing so they stop growing or die. Radiation
      therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with
      chemotherapy may kill more tumor cells. Autologous stem cell transplant may be able to
      replace blood-forming cells that were destroyed by chemotherapy or radiation therapy. It is
      not yet known which radiation therapy regimen combined with chemotherapy and donor stem cell
      transplant is more effective in treating medulloblastoma, supratentorial primitive
      neuroectodermal tumor, or atypical teratoid rhabdoid tumor.

      This phase III trial is studying two different regimens of radiation therapy when given
      together with chemotherapy and autologous stem cell transplant to see how well they work in
      treating patients with newly diagnosed medulloblastoma, supratentorial primitive
      neuroectodermal tumor, or atypical teratoid rhabdoid tumor.

      PRIMARY OBJECTIVE:

        -  To assess the relationship between ERBB2 protein expression in tumors and
           progression-free survival probability for patients with medulloblastoma.

        -  To estimate the frequency of mutations associated with SHH and WNT tumors (as defined by
           gene expression profiling) via targeted sequencing performed in an independent cohort of
           WNT and SHH tumors (also defined by gene expression profiling).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SECONDARY OBJECTIVES:

        -  To compare the effects of a computer-based training system specifically targeting
           language, reading, and learning skills (Fast ForWord, Scientific Learning Corporation)
           with the current standard of care on reading decoding skills as measured by individual
           academic testing.

        -  To monitor for treatment failure in the posterior fossa of patients whose tumor bed
           receives a reduced volume of radiation.

        -  To correlate radiation dosimetry of target and normal tissues with rate and patterns of
           failure and longitudinal measures of audiometric, endocrine and cognitive effects.

      EXPLORATORY OBJECTIVES:

        -  To estimate the change in neuropsychological performance from the neuropsychology
           assessment battery (intellect, academic achievement and cognitive ability) and examine
           the relationship of these changes to risk group, age at diagnosis, and parent measures.

        -  To evaluate the differences between neurotoxicity in the average-risk patient group with
           that in the high-risk group through qMRI, and fMRI.

        -  To develop or refine novel models relating impact of medulloblastoma therapy on
           neurocognitive performance to quantitative and functional neuroimaging measures.

      OUTLINE: This is a multicenter study. Patients are stratified according to disease risk
      (high-risk disease vs average-risk disease).

      Patients in both strata undergo peripheral blood stem cell or bone marrow harvest.

        -  Stratum 1 (high-risk group):

             -  Radiotherapy: Patients undergo craniospinal radiotherapy once daily 5 days a week
                for 6 weeks.

             -  High-dose chemotherapy and autologous stem cell transplantation (SCT): Six weeks
                after the completion of radiotherapy, patients receive high-dose chemotherapy
                comprising vincristine IV followed by cisplatin IV over 6 hours on day -4 and
                cyclophosphamide IV over 1 hour on days -3 and -2. Patients undergo autologous SCT
                on day 0. Patients receive filgrastim (G-CSF) subcutaneously beginning on day 1 and
                continuing until blood counts recover. Patients receive vincristine IV on day 6.
                High-dose chemotherapy and autologous SCT repeat every 4 weeks for 3 additional
                courses in the absence of unacceptable toxicity.

        -  Stratum 2 (average-risk group):

             -  Radiotherapy: Patients undergo craniospinal radiotherapy as in stratum 1, but at a
                lower dose.

             -  High-dose chemotherapy and autologous SCT: Patients receive high-dose chemotherapy,
                autologous SCT, G-CSF, and post-transplantation vincristine as in stratum 1.

      Some patients undergo a neuropsychology assessment at baseline, before chemotherapy, and then
      annually for 5 years.

      After completion of study therapy, patients are followed every 3 months until month 30 (2.5
      years) after diagnosis and then every 6 months until month 72 (6 years) after diagnosis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors</measure>
    <time_frame>2 years after tumor cell analysis in 122 participants</time_frame>
    <description>The relationship between ERBB2 protein expression in tumors and progression-free survival was assessed in 122 participants with a diagnosis of medulloblastoma and with ERBB2 protein assessments. If the ERBB2 value was greater than zero, the ERBB2 was defined as positive for the participant. If the ERBB2 value was zero, the ERBB2 was defined as negative. Progression-free survival was calculated from the date of diagnosis to the date of disease progression/relapse, the date of death, or the date of last contact. The log-rank test was used to compare the PFS distributions of ERBB2 groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) Compared Between ERBB2 Assessment and Risk Group.</measure>
    <time_frame>2 years after tumor cell analysis in 122 participants</time_frame>
    <description>122 participants with a diagnosis of medulloblastoma were grouped by ERBB2 positive/negative assessment and risk group into 4 groups. Progression-free survival was calculated from the date of diagnosis to the date of disease progression/relapse, the date of death, or the date of last contact. The log-rank test was used to compare the PFS distributions of ERBB2 groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Mutations Associated With SHH and WNT Tumors</measure>
    <time_frame>within 3.5 years following completion of accrual</time_frame>
    <description>The frequency of mutations for the main genes associated with SHH and WNT tumors identified via targeted sequencing based on formalin fixed paraffin embedded material is provided.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reading Decoding Composite Scores in the Intervention and Standard of Care Groups</measure>
    <time_frame>Measurements will be made at time of randomization, at 3 months from initiation of treatment, and yearly thereafter for 10 years</time_frame>
    <description>To compare the effects of a computer-based training system specifically targeting language, reading, and learning skills (Fast ForWord, Scientific Learning Corporation) with the current standard of care on reading decoding skills as measured by individual academic testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Average Risk Patients Whose Treatment Failure Included the Posterior Fossa</measure>
    <time_frame>Annually for 6 years post irradiation</time_frame>
    <description>To monitor for treatment failure in the posterior fossa of patients whose tumor bed receives a reduced volume of radiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean RT Dose to Specified Target Tissue Volume by Rate and Pattern of Failure, e.g. Local Failure, Distant Failure, Etc.</measure>
    <time_frame>Once all patients have been followed for 2 years</time_frame>
    <description>To correlate radiation dosimetry of target and normal tissues with rate and patterns of failure and longitudinal measures of audiometric, endocrine and cognitive effects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">416</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Stratum 1 (high-risk group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks. Six weeks after the completion of radiotherapy, patients receive high-dose chemotherapy followed by autologous stem cell transplantation (SCT) and filgrastim (G-CSF) with post-transplantation vincristine. High-dose chemotherapy and autologous SCT repeat every 4 weeks for 3 additional courses in the absence of unacceptable toxicity.
Interventions: vincristine, cisplatin, cyclophosphamide, autologous hematopoietic stem cell transplantation, filgrastim, radiation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum 2 (average-risk group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo craniospinal radiotherapy as in stratum 1, but at a lower dose. Patients receive high-dose chemotherapy, autologous SCT, G-CSF, and post-transplantation vincristine as in stratum 1.
Interventions: vincristine, cisplatin, cyclophosphamide, autologous hematopoietic stem cell transplantation, filgrastim, radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Stratum 1 (high-risk group)</arm_group_label>
    <arm_group_label>Stratum 2 (average-risk group)</arm_group_label>
    <other_name>Neupogen(R)</other_name>
    <other_name>G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Stratum 1 (high-risk group)</arm_group_label>
    <arm_group_label>Stratum 2 (average-risk group)</arm_group_label>
    <other_name>Platinol-AQ(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Stratum 1 (high-risk group)</arm_group_label>
    <arm_group_label>Stratum 2 (average-risk group)</arm_group_label>
    <other_name>Cytoxan(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Stratum 1 (high-risk group)</arm_group_label>
    <arm_group_label>Stratum 2 (average-risk group)</arm_group_label>
    <other_name>Oncovin(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell transplantation</intervention_name>
    <description>Patients undergo autologous stem cell transplantation</description>
    <arm_group_label>Stratum 1 (high-risk group)</arm_group_label>
    <arm_group_label>Stratum 2 (average-risk group)</arm_group_label>
    <other_name>autologous HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks.</description>
    <arm_group_label>Stratum 1 (high-risk group)</arm_group_label>
    <arm_group_label>Stratum 2 (average-risk group)</arm_group_label>
    <other_name>RT</other_name>
    <other_name>Craniospinal radiotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed diagnosis of 1 of the following:

               -  Medulloblastoma

               -  Supratentorial primitive neuroectodermal tumor (PNET)

               -  PNET variants (ependymoblastoma, pineoblastoma, CNS neuroblastoma)

               -  Atypical teratoid rhabdoid tumor (ATRT)

          -  Definitive surgery for CNS tumor within the past 31 days

          -  Meets one of the following risk criteria:

               -  Average-risk disease

                    -  Localized disease with no overt evidence of invasion beyond the posterior
                       fossa (or supratentorial compartment for PNET or ATRT) by intraoperative
                       observations of the neurosurgeon AND postoperative CT scan or MRI

                    -  T4 disease eligible if all of the following are true:

                         -  Gross total resection determined by intraoperative observations of the
                            neurosurgeon AND postoperative CT scan or MRI

                         -  Residual tumor or imaging abnormality whose size is &lt; 1.5 cm^2

                         -  No evidence of CNS or extraneural metastasis by MRI of the spine (with
                            and without contrast agent) or CT-based myelogram AND by cytologic
                            examination of the lumbar cerebral spinal fluid (CSF) 14-28 days after
                            surgery

                    -  Brain stem invasion allowed in the absence of residual tumor (tumor &lt; 1.5
                       cm^2 by imaging)

               -  High-risk disease meeting one of the following criteria:

                    -  Metastatic disease within the neuraxis (i.e., evidence of subarachnoid
                       dissemination by imaging and/or cytologic examination of CSF)

                    -  Presence of residual disease &gt; 1.5 cm^2 at the primary site after surgery

        PATIENT CHARACTERISTICS:

        Age

          -  3 to 21 at diagnosis

        Performance status

          -  Lansky 30-100% (&lt; 10 years old)

          -  Karnofsky 30-100% (≥ 10 years old) (except for posterior fossa syndrome)

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Hemoglobin &gt; 8 g/dL

          -  WBC &gt; 2,000/mm^3

          -  Absolute neutrophil count &gt; 500/mm^3

          -  Platelet count &gt; 50,000/mm^3

        Hepatic

          -  ALT &lt; 5 times normal

          -  Bilirubin &lt; 3.0 mg/dL

        Renal

          -  Creatinine &lt; 2.0 mg/dL OR

          -  Creatinine clearance &gt; 70 mL/min

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy

        Endocrine therapy

          -  Prior corticosteroid therapy allowed

        Radiotherapy

          -  No prior radiotherapy

        Surgery

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amar Gajjar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2399</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lady Cilento Children's Hospital, Brisbane</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <results_first_submitted>November 4, 2013</results_first_submitted>
  <results_first_submitted_qc>January 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 27, 2014</results_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>untreated childhood medulloblastoma</keyword>
  <keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
  <keyword>untreated childhood pineoblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Rhabdoid Tumor</mesh_term>
    <mesh_term>Teratoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>416 participants were enrolled between 9/9/2003 and 3/7/2013.</recruitment_details>
      <pre_assignment_details>Of the 416 participants enrolled, three were ineligible and taken off study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Average-Risk Group</title>
          <description>Participants assigned to the average-risk arm had localized tumor without overt evidence of invasion beyond the posterior fossa (or supratentorial compartment for PNET's/ATRT). Participants with T4 disease met the following criteria: gross total resection defined as residual tumor or imaging abnormality whose size was &lt;1.5 cm^2 on postoperative CT or MR images, no evidence of CNS or extraneural metastasis, and brain stem invasion by the tumor in the absence of imaging evidence of residual tumor (tumor size &lt;1.5 cm^2).</description>
        </group>
        <group group_id="P2">
          <title>High-Risk Group</title>
          <description>Participants assigned to the high-risk arm were determined to have the presence of metastatic disease within the neuraxis (i.e., evidence of subarachnoid dissemination), OR presence of residual disease (≥1.5 cm^2) at the primary site after surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="269"/>
                <participants group_id="P2" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="251"/>
                <participants group_id="P2" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Still on therapy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Bone involvement confirmed by bone scan</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excessive toxicity</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-specified</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants had a diagnosis of medulloblastoma, supratentorial primitive neuroectodermal tumor (PNET), PNET variants (ependymoblastoma, pineoblastoma, CNS neuroblastoma), or atypical teratoid rhabdoid tumor (ATRT).</population>
      <group_list>
        <group group_id="B1">
          <title>Average-Risk Group</title>
          <description>Participants assigned to the average-risk arm had localized tumor without overt evidence of invasion beyond the posterior fossa (or supratentorial compartment for PNET's/ATRT). Participants with T4 disease met the following criteria: gross total resection defined as residual tumor or imaging abnormality whose size was &lt;1.5 cm^2 on postoperative CT or MR images, no evidence of CNS or extraneural metastasis, and brain stem invasion by the tumor in the absence of imaging evidence of residual tumor (tumor size &lt;1.5 cm^2).</description>
        </group>
        <group group_id="B2">
          <title>High-Risk Group</title>
          <description>Participants assigned to the high-risk arm were determined to have the presence of metastatic disease within the neuraxis (i.e., evidence of subarachnoid dissemination), OR presence of residual disease (≥1.5 cm^2) at the primary site after surgery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="269"/>
            <count group_id="B2" value="144"/>
            <count group_id="B3" value="413"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.15" spread="4.08"/>
                    <measurement group_id="B2" value="8.66" spread="3.93"/>
                    <measurement group_id="B3" value="8.98" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.42" lower_limit="3.06" upper_limit="21.56"/>
                    <measurement group_id="B2" value="7.87" lower_limit="3.13" upper_limit="20.43"/>
                    <measurement group_id="B3" value="8.33" lower_limit="3.06" upper_limit="21.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors</title>
        <description>The relationship between ERBB2 protein expression in tumors and progression-free survival was assessed in 122 participants with a diagnosis of medulloblastoma and with ERBB2 protein assessments. If the ERBB2 value was greater than zero, the ERBB2 was defined as positive for the participant. If the ERBB2 value was zero, the ERBB2 was defined as negative. Progression-free survival was calculated from the date of diagnosis to the date of disease progression/relapse, the date of death, or the date of last contact. The log-rank test was used to compare the PFS distributions of ERBB2 groups.</description>
        <time_frame>2 years after tumor cell analysis in 122 participants</time_frame>
        <population>Analysis included the first 122 participants with a diagnosis of medulloblastoma and with fresh tissue and ERBB2 protein assessments. Participants with a diagnosis of PNET, PNET variants, or ATRT were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study</title>
            <description>Analysis included the first 122 participants with a diagnosis of medulloblastoma and with fresh tissue and ERBB2 protein assessments. Participants with a diagnosis of supratentorial primitive neuroectodermal tumor (PNET), PNET variants (ependymoblastoma, pineoblastoma, CNS neuroblastoma), or atypical teratoid rhabdoid tumor (ATRT) were not included in the analysis of ERBB2 tumors.</description>
          </group>
          <group group_id="O2">
            <title>Average-Risk Group</title>
            <description>Participants assigned to the average-risk arm had localized tumor without overt evidence of invasion beyond the posterior fossa. Participants with T4 disease met the following criteria: gross total resection defined as residual tumor or imaging abnormality whose size was &lt;1.5 cm^2 on postoperative CT or MR images, no evidence of CNS or extraneural metastasis, and brain stem invasion by the tumor in the absence of imaging evidence of residual tumor (tumor size &lt;1.5 cm^2).</description>
          </group>
          <group group_id="O3">
            <title>High-Risk Group</title>
            <description>Participants assigned to the high-risk arm were determined to have the presence of metastatic disease within the neuraxis (i.e., evidence of subarachnoid dissemination), OR presence of residual disease (≥1.5 cm^2) at the primary site after surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors</title>
          <description>The relationship between ERBB2 protein expression in tumors and progression-free survival was assessed in 122 participants with a diagnosis of medulloblastoma and with ERBB2 protein assessments. If the ERBB2 value was greater than zero, the ERBB2 was defined as positive for the participant. If the ERBB2 value was zero, the ERBB2 was defined as negative. Progression-free survival was calculated from the date of diagnosis to the date of disease progression/relapse, the date of death, or the date of last contact. The log-rank test was used to compare the PFS distributions of ERBB2 groups.</description>
          <population>Analysis included the first 122 participants with a diagnosis of medulloblastoma and with fresh tissue and ERBB2 protein assessments. Participants with a diagnosis of PNET, PNET variants, or ATRT were not included in this analysis.</population>
          <units>probability of PFS at 2 years</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="85"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive ERBB2 (77, 54, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.792" spread="0.045"/>
                    <measurement group_id="O2" value="0.833" spread="0.050"/>
                    <measurement group_id="O3" value="0.696" spread="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative ERBB2 (45, 31, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.867" spread="0.050"/>
                    <measurement group_id="O2" value="0.935" spread="0.043"/>
                    <measurement group_id="O3" value="0.714" spread="0.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8001</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5195</p_value>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7696</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS) Compared Between ERBB2 Assessment and Risk Group.</title>
        <description>122 participants with a diagnosis of medulloblastoma were grouped by ERBB2 positive/negative assessment and risk group into 4 groups. Progression-free survival was calculated from the date of diagnosis to the date of disease progression/relapse, the date of death, or the date of last contact. The log-rank test was used to compare the PFS distributions of ERBB2 groups.</description>
        <time_frame>2 years after tumor cell analysis in 122 participants</time_frame>
        <population>Analysis was completed for the first 122 participants with a diagnosis of medulloblastoma and with fresh tissue and ERBB2 protein assessments. Participants with a diagnosis of PNET, PNET variants, or ATRT were not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ERBB2 Positive &amp; Average Risk</title>
            <description>54 participants who were ERBB2 positive and in the average risk group.</description>
          </group>
          <group group_id="O2">
            <title>ERBB2 Positive &amp; High Risk</title>
            <description>23 participants who were ERBB2 positive and in the high risk group</description>
          </group>
          <group group_id="O3">
            <title>ERBB2 Negative &amp; Average Risk</title>
            <description>31 participants who were ERBB2 negative and in the average risk group</description>
          </group>
          <group group_id="O4">
            <title>ERBB2 Negative &amp; High Risk</title>
            <description>14 participants who were ERBB2 negative and in the high risk group</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) Compared Between ERBB2 Assessment and Risk Group.</title>
          <description>122 participants with a diagnosis of medulloblastoma were grouped by ERBB2 positive/negative assessment and risk group into 4 groups. Progression-free survival was calculated from the date of diagnosis to the date of disease progression/relapse, the date of death, or the date of last contact. The log-rank test was used to compare the PFS distributions of ERBB2 groups.</description>
          <population>Analysis was completed for the first 122 participants with a diagnosis of medulloblastoma and with fresh tissue and ERBB2 protein assessments. Participants with a diagnosis of PNET, PNET variants, or ATRT were not included in this analysis.</population>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.833" spread="0.050"/>
                    <measurement group_id="O2" value="0.696" spread="0.096"/>
                    <measurement group_id="O3" value="0.935" spread="0.043"/>
                    <measurement group_id="O4" value="0.714" spread="0.115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0206</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Mutations Associated With SHH and WNT Tumors</title>
        <description>The frequency of mutations for the main genes associated with SHH and WNT tumors identified via targeted sequencing based on formalin fixed paraffin embedded material is provided.</description>
        <time_frame>within 3.5 years following completion of accrual</time_frame>
        <population>Only patients with WNT and SHH tumors with available tissue for targeted sequencing were analyzed for frequency of mutation. WNT and SHH subgroups were identified by methylation profiling.</population>
        <group_list>
          <group group_id="O1">
            <title>SHH Pathway - In/Del Somatic</title>
            <description>Tissue from this subgroup of patients was analyzed for somatic insertion/deletion (In/Del).</description>
          </group>
          <group group_id="O2">
            <title>WNT Pathway - In/Del Somatic</title>
            <description>Tissue from this subgroup of patients was analyzed for somatic insertion/deletion (In/Del).</description>
          </group>
          <group group_id="O3">
            <title>SHH Pathway - In/Del Germline</title>
            <description>Tissue from this subgroup of patients was analyzed for germline insertion/deletion (In/Del).</description>
          </group>
          <group group_id="O4">
            <title>WNT Pathway - In/Del Germline</title>
            <description>Tissue from this subgroup of patients was analyzed for germline insertion/deletion (In/Del).</description>
          </group>
          <group group_id="O5">
            <title>SHH Pathway - SNV Somatic</title>
            <description>Tissue from this subgroup of patients was analyzed for somatic single nucleotide variation (SNV).</description>
          </group>
          <group group_id="O6">
            <title>WNT Pathway - SNV Somatic</title>
            <description>Tissue from this subgroup of patients was analyzed for somatic single nucleotide variation (SNV).</description>
          </group>
          <group group_id="O7">
            <title>SHH Pathway - SNV Germline</title>
            <description>Tissue from this subgroup of patients was analyzed for germline single nucleotide variation (SNV).</description>
          </group>
          <group group_id="O8">
            <title>WNT Pathway - SNV Germline</title>
            <description>Tissue from this subgroup of patients was analyzed for germline single nucleotide variation (SNV).</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Mutations Associated With SHH and WNT Tumors</title>
          <description>The frequency of mutations for the main genes associated with SHH and WNT tumors identified via targeted sequencing based on formalin fixed paraffin embedded material is provided.</description>
          <population>Only patients with WNT and SHH tumors with available tissue for targeted sequencing were analyzed for frequency of mutation. WNT and SHH subgroups were identified by methylation profiling.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="20"/>
                <count group_id="O8" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PTCH1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DDX3X</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TP53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KMT2D</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SUFU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CREBBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GLI2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TCF4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTEN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>KMT2C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FBXW7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSE1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTNNB1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMARCA4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PIK3CA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>APC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EPHA7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARID1A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARID2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ATM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRCA2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reading Decoding Composite Scores in the Intervention and Standard of Care Groups</title>
        <description>To compare the effects of a computer-based training system specifically targeting language, reading, and learning skills (Fast ForWord, Scientific Learning Corporation) with the current standard of care on reading decoding skills as measured by individual academic testing.</description>
        <time_frame>Measurements will be made at time of randomization, at 3 months from initiation of treatment, and yearly thereafter for 10 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Average Risk Patients Whose Treatment Failure Included the Posterior Fossa</title>
        <description>To monitor for treatment failure in the posterior fossa of patients whose tumor bed receives a reduced volume of radiation.</description>
        <time_frame>Annually for 6 years post irradiation</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean RT Dose to Specified Target Tissue Volume by Rate and Pattern of Failure, e.g. Local Failure, Distant Failure, Etc.</title>
        <description>To correlate radiation dosimetry of target and normal tissues with rate and patterns of failure and longitudinal measures of audiometric, endocrine and cognitive effects.</description>
        <time_frame>Once all patients have been followed for 2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) are reported through 9/17/2013 and include all grade 3, 4 and 5 events occurring during treatment to 30 days after treatment end, and events occurring &gt;30 days after treatment end and felt to be possibly related to protocol treatment.</time_frame>
      <desc>Per protocol, Grade 3 and 4 hematologic toxicities, grade 3 and 4 electrolyte abnormalities, and total parenteral nutrition or intravenous fluids administered to prevent significant weight loss/malnutrition were not collected if they occurred from the beginning of radiation therapy through the end of 4 courses of high dose chemotherapy.</desc>
      <group_list>
        <group group_id="E1">
          <title>Average-Risk Group</title>
          <description>Participants assigned to the average-risk arm had localized tumor without overt evidence of invasion beyond the posterior fossa (or supratentorial compartment for PNET's/ATRT). Participants with T4 disease met the following criteria: gross total resection defined as residual tumor or imaging abnormality whose size was &lt;1.5 cm^2 on postoperative CT or MR images, no evidence of CNS or extraneural metastasis, and brain stem invasion by the tumor in the absence of imaging evidence of residual tumor (tumor size &lt;1.5 cm^2).</description>
        </group>
        <group group_id="E2">
          <title>High-Risk Group</title>
          <description>Participants assigned to the high-risk arm were determined to have the presence of metastatic disease within the neuraxis (i.e., evidence of subarachnoid dissemination), OR presence of residual disease (≥1.5 cm^2) at the primary site after surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular and nodal arrhythmia - sinus bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Cardiac general - other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Pericardial effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death not associated with CTCAE term, death NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Syndromes - other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Pain - other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Fever of unknown origin without clinically or microbiologically documented infection (ANC &lt;1.0 x 10e9/L).</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Infection, blood</sub_title>
                <description>Documented clinically or microbiologically with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L).</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, blood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, lung (pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, meninges (meningitis)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, meninges (meningitis)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis (metabolic or respiratory)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/soft tissue - other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Apnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>CNS necrosis/cystic progression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Leak, cerebrospinal fluid (CSF)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy (radiographic findings)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Personality/behavioral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="269"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Somnolence/depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Syncope (fainting)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult Respiratory Distress Syndrome (ARDS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="269"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis (radiographic changes)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Pulmonary/upper respiratory - other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <description>e.g., thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Hemorrhage/bleeding - other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="269"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="236" subjects_at_risk="269"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="269"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="25" subjects_affected="15" subjects_at_risk="269"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing: patients with/without baseline audiogram and enrolled in a monitoring program</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="269"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="63" subjects_affected="53" subjects_at_risk="269"/>
                <counts group_id="E2" events="29" subjects_affected="21" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="30" subjects_affected="27" subjects_at_risk="269"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="36" subjects_affected="23" subjects_at_risk="269"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="269"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, abdomen NOS</sub_title>
                <counts group_id="E1" events="37" subjects_affected="33" subjects_at_risk="269"/>
                <counts group_id="E2" events="30" subjects_affected="17" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Pain, head/headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="269"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="54" subjects_affected="39" subjects_at_risk="269"/>
                <counts group_id="E2" events="32" subjects_affected="23" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>Fever of unknown origin without clinically or microbiologically documented infection (ANC &lt;1.0 x 10e9/L).</description>
                <counts group_id="E1" events="383" subjects_affected="172" subjects_at_risk="269"/>
                <counts group_id="E2" events="148" subjects_affected="77" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Infection, blood</sub_title>
                <description>Documented clinically or microbiologically with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L).</description>
                <counts group_id="E1" events="76" subjects_affected="55" subjects_at_risk="269"/>
                <counts group_id="E2" events="28" subjects_affected="24" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Infection - other</sub_title>
                <counts group_id="E1" events="33" subjects_affected="25" subjects_at_risk="269"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Colitis, infectious (e.g., Clostridium difficile)</sub_title>
                <counts group_id="E1" events="28" subjects_affected="22" subjects_at_risk="269"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, blood</sub_title>
                <counts group_id="E1" events="30" subjects_affected="21" subjects_at_risk="269"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC, blood</sub_title>
                <counts group_id="E1" events="23" subjects_affected="17" subjects_at_risk="269"/>
                <counts group_id="E2" events="19" subjects_affected="13" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Infection with normal ANC or Grade 1 or 2 neutrophils, catheter-related</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="269"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Infection, catheter-related</sub_title>
                <description>Documented clinically or microbiologically with Grade 3 or 4 neutrophils (ANC &lt;1.0 x 10e9/L).</description>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="269"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage, pulmonary/upper respiratory, nose</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="269"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study is ongoing. Participant flow and adverse events will be updated as additional outcomes are reported.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Amar Gajjar, MD</name_or_title>
      <organization>St. Jude Children's Research Hospital</organization>
      <phone>866-278-5833</phone>
      <email>info@stjude.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

